Abstract:
The present invention relates to a liposome comprising an elastin-like polypeptide (ELP) conjugated to a moiety containing a hydrophobic group, a chemosensitizer, and an anticancer agent, wherein the ELP conjugated to moiety containing the hydrophobic group is filled in a lipid bilayer. The present invention provides a pharmaceutical composition including the liposome and a method for delivering the chemosensitizer and the anticancer agent to a target site of a subject by using the liposome. [Reference numerals] (AA) Cell viability(%); (BB) Free doxorubicin; (CC) Glass doxorubicin
Abstract:
One embodiment of the present invention relates to a metabolism network model of Corynebacterium glutamicum for producing 1,4-BDO by Corynebacterium glutamicum, which is a strain that does not produce 1,4-BDO in a natural state. On the basis of the network model, metabolic properties of Corynebacterium glutamicum are analyzed. By predicting effects of a deletion target enzyme (ldhA, mqo or mdh) in a state in which Cat1, sucD, 4hbD, cat2 and adhE are included, and removing them, production efficiency of 1,4-BDO and increase of 1,4-BDO under the same fermentation conditions are confirmed. In addition, transformation microorganism produced by the method can produce 1,4-BDO in high efficiency, and therefore, can be effectively used in the industries.
Abstract:
PURPOSE: A liposome containing an elastine-like polypeptide(ELP) and a use thereof are provided to reduce the amount of drug release, and to maintain stable state. CONSTITUTION: A liposome contains: a lipid bilayer; an elastine-like polypeptide(ELP) in which hydrophobic group-containing moiety is conjugated; and a lipid bilayer stabilizing agent. The moiety is filled in the lipid bilayer. The lipid bilayer stabilizing agent is steroid which is incorporated in the lipid bilayer. The lipid bilayer stabilizing agent is selected from the group consisting of sterol or a derivative thereof, spingolipid or a derivative thereof, and a combination thereof. The lipid bilayer stabilizing agent is selected from the group consisting of cholesterol, beta-cholesterol, sistosterol, ergosterol, stigmasterol, 4,22 stigmastadiene-3-one, stigmasterol acetate, lanosterol, and a combination thereof. [Reference numerals] (AA) Calcein release(%); (BB) Cholesterol molar ratio: 25.8; (CC) Cholesterol molar ratio: 41; (DD) Temperature(°C);
Abstract:
PURPOSE: A modified microorganism with improved xylose utilization is provided to produce chemical materials. CONSTITUTION: A modified microorganism converts xylose into xylitol by xylose reductase, xylitol into xylulose by xylitol dehydrogenase, and xylulose into xylulose-5-phosphate by xylulokinase. The microorganism produces a chemical material using xylose. Xylose is converted into xylitol by xylose reductase. The xylose reductase and xylitol dehydrogenase activities are derived from Pichia stipitis. The xylulokinase activity is derived from Saccharomyces cerevisiae. The modified microorganism is E.coli or Kluyveromyces marxianus. The chemical material includes alcohol, organic acid, amino acid, or vitamin. The modified microorganism is deposited by deposit number KCTC11951BP, KCTC11952BP or KCTC11953BP.
Abstract:
PURPOSE: A recombinant microorganism which produces 3-hydroxypropionic acid(3-HP) using a malonic semialdehyde reduction pathway is provided to remarkably enhance 3-HP productivity by gene manipulation. CONSTITUTION: A recombinant microorganism for producing 3-hydroxypropionic acid has a pathway for sequentially producing pyruvate, acetyl Co, malonyl-CoA, and malonic semialdehyde. The microorganism includes Escherichia sp., Saccharomyces sp., or Kluyveromyces sp. A gene encoding lactate dehydrogenase is IdhA or a homolog or a variant thereof. A gene encoding phosphotransacetylase is pta or a homolog or a variant thereof.
Abstract:
PURPOSE: A modified microorganism for producing lactic acids and a method for producing lactic acids are provided to produce lactic acids with high efficiency under an acidic condition. CONSTITUTION: A modified microorganism for producing lactic acids with high efficiency has LDH activity of Pelodiscus sinensis japonicus, Ornithorhynchus anatinus, Tursiops truncates, and Rattus norvegicus. The modified microorganism is yeast or bacteria. The modified microorganism is E.coli or Kluyveromyces marxianus. The modified microorganism produces lactic acids with 12.2% or more of glucose. An expression vector for producing the modified microorganism comprises: a replication origin; a promoter; a polynucleotide; and a terminator. A method for producing lactic acids comprises: a step of culturing the modified microorganism in a medium containing glucose; and a step of collecting lactic acids from the culture.
Abstract:
PURPOSE: A modified microorganism for producing lactic acids is provided to prepare lactic acids with high efficiency under an acidic condition. CONSTITUTION: A modified microorganism for producing lactic acids has a lactate dehydrogenase(LDH) activity of Pelodiscus sinensis japonicus, Ornithorhynchus anatinus, Tursiops truncates, or Rattus norvegicus. The modified microorganism is Escherichia sp. or Kluyveromyces sp. The modified microorganism produces lactic acids with 34% or more of glucose. An expression vector contains: a replication origin for constructing the modified microroganisms; a promoter; a polynucleotide coding LDH activation of one or more species selected from the group consisting of Pelodiscus sinensis japonicus, Ornithorhynchus anatinus, Tursiops truncates, or Rattus norvegicus; and a terminator. The replication origin is ARS/CEN replication origin.
Abstract:
PURPOSE: An expression vector which overexpresses target proteins, and a method for producing the target protein are provided to obtain the proteins in K. marxianus. CONSTITUTION: An expression vector contains: a replication origin; a CYC promoter, a TEF promoter, a GPD promoter, or an ADH promoter; and a terminator. The CYC promoter contains a sequence of sequence number 1 or a sequence having 70% or more sequence homology with the sequence of sequence number 1. The TEF promoter has a sequence of sequence number 2 or a sequence with 70% or more sequence homology with the sequence of sequence number 2. GPD promoter contains a sequence of sequence number 3 or a sequence having 70% or more homology with the sequence of sequence number 3. The ADH promoter has a sequence of sequence number 4 or a sequence having 70% or more sequence homology with the sequence of sequence number 4.